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“Seventy is old enough. After that there is too much risk.”
—Mark Twain (1)
Mark Twain’s 19th-century sentiment regarding old age is
shared by many cardiologists in the current century when
considering the use of invasive procedures or pharmacologic
therapies in the elderly, particularly in those over 80 years of
age. It is certainly true that advanced age leads to increased
risk with coronary surgery, percutaneous coronary interven-
tions (PCI), and the use of drugs such as thrombolytic
agents. Paradoxically, these are precisely the patients that
may benefit the most. Thus, it is important to understand
the risks and benefits of these therapies in elderly persons
before they are either widely used and assumed safe or
summarily dismissed as being too risky.
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This issue is of increasing importance in the U.S. and
other nations faced with a progressive growth in the elderly
population. Based on the year 2000 census, there are over 9
million Americans age 80 years or more and over 4 million
age 85 years or more (2). Population projections suggest that
over the next 50 years, the greatest growth will be in those
age 85 years and over, with an estimated 8.5 million
Americans in this age group by 2030 and more than 18
million by 2050 (2). Given the marked prevalence of heart
disease in the elderly, cardiologists face a future where a
substantial number of their patients will be octogenarians or
older.
Although coronary surgery can be performed safely in
highly selected octogenarians, most patients age 80 years or
more either have significant comorbid illness which makes
surgery a prohibitive risk or they simply chose not to
undergo this procedure. Percutaneous procedures are much
more palatable to the mindset of the elderly as well as their
physicians. How safe and effective are PCI procedures in
elderly patients? Recently, the results of two registries
reported the clinical outcomes from a total of nearly 11,000
PCI procedures in octogenarians in the current era (2,3). As
might be expected, this population had a high frequency of
comorbid illness such as diabetes (23%), previous bypass
surgery (24%), previous stroke (18%), and renal failure
(11%) (3). For the most part, PCI is performed for acute
coronary syndromes or recent myocardial infarction (MI)
rather than for elective, stable syndromes. Over half of these
patients have multi-vessel coronary disease. Despite this,
these studies confirm that PCI in octogenarians may lead to
acceptable early results. Angiographic success is high, and
the overall hospital mortality was 3.7% (3,4). Mortality was
closely linked to timing of MI, with the lowest mortality
(1.35%) seen if there was no MI, and the highest mortality
(13.79%) seen if MI was within the past 6 h (4). Other
significant in-hospital complications included stroke in
0.46% and 0.68% (3,4), renal failure in 2.15%, and major
vascular complications in 3.73% (4).
The large-scale registries suggest that PCI can be per-
formed in octogenarians with an acceptable risk. Whether
this aged population actually achieves a longer term benefit
from revascularization procedures is another question en-
tirely. A large population study from Canada comparing the
outcomes of revascularization versus medical therapy in
elderly patients found that revascularization was associated
with better survival in all elderly subgroups, but the greatest
absolute survival difference was seen in patients over 80
years of age (5). Patients70 years old had survival rates for
bypass surgery, PCI, and medical therapy of 95%, 94%, and
91%, respectively, whereas patients more than 80 years of
age had survival rates of 77% with surgery, 72% with PCI,
and 60% with medical therapy.
Survival is probably not the most important outcome in
the elderly. Patients in their 80s almost universally declare
that quality of life takes precedence over measures that
prolong survival. Few studies have specifically addressed
quality-of-life measures in elderly patients receiving medical
therapy versus PCI. In the Trial of Invasive versus Medical
therapy in Elderly (TIME), 301 patients 75 years of age
with chronic angina on at least two anti-anginal drugs were
randomized to coronary angiography and revascularization
versus optimized medical therapy (6). The primary end
points were indices of quality of life and the presence of
major adverse event (death, non-fatal MI, hospital admis-
sion for acute coronary syndrome) at six months. Although
these patients likely represented a select group of elderly
individuals, their clinical characteristics were similar to the
large registries with similar proportions of comorbidities
and multi-vessel coronary disease. Among the group ran-
domized to an invasive approach, 109 (74%) underwent
revascularization procedures, with PCI in 79 (72%) and
coronary artery bypass graft surgery (CABG) in 30 (28%).
Mortality related to revascularization was 2.5%. In both the
invasive and medical groups, the indices of quality of life
improved. Angina severity decreased in both groups but
more significantly in patients randomized to an invasive
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approach. At six months, adverse cardiac events occurred in
49% of the medical group and 19% of the invasive group and
were due primarily to higher rates of hospital admissions for
acute coronary syndromes and non-fatal MI in the medical
group. These data suggest that patients age 75 years or older
with angina have less symptoms, less hospital readmissions,
and a better quality of life after revascularization (primarily
accomplished with PCI) compared with medical therapy.
The proportion of elderly patients who might benefit
from PCI is not known. Many octogenarians might not be
considered for an invasive procedure because of their asso-
ciated illnesses or poor general health status. Even among
those felt to be good candidates for revascularization, a
sizeable proportion of patients are found to have untreatable
coronary disease. As a clinician, it is hard to know which
octogenarians should be chosen for an invasive approach. In
the TIME trial, 74% of patients randomized to an invasive
strategy underwent revascularization, with most of these
undergoing PCI. The remaining patients were treated
medically either because of refusal (7/37), the identification
of non-critical disease (11/37), or the presence of disease not
amenable to either PCI or CABG (19/37). Thus, even in a
select group, roughly one-quarter of elderly patients will
either have disease not amenable to revascularization or will
have insignificant disease.
Once a physician has decided to perform PCI in an
octogenarian, the next decision regards the use of adjunctive
pharmacology. The randomized controlled trials have estab-
lished that adjunctive glycoprotein (GP) IIb/IIIa inhibitors
reduce MI and death in numerous clinical subsets involving
PCI (7–14). Importantly, they have been shown to be safe
with low rates of major bleeding, especially when heparin is
discontinued after the procedure (14). Because randomized
trials represent only a small fraction of the total population
being treated, the conclusions made from these studies may
be difficult to extrapolate to specific patient subsets that
were either excluded or underrepresented in the randomized
trials. This is particularly true with elderly patients. At least
one major trial of GP IIb/IIIa inhibitors in PCI excluded
patients age 80 years (7), and the mean age of patients in
all the other trials was only about 60 years.
There are no randomized comparisons determining the
efficacy of GP IIb/IIIa inhibitors versus placebo in octoge-
narians undergoing PCI. Thus, the utility of these agents in
this population is unknown. Subgroup analysis from the
randomized trials provides some insights into this question.
Several studies specifically analyzed the primary end point in
patients more than 65 years old and showed a benefit of GP
IIb/IIIa inhibitors compared with placebo (Figs. 1 and 2).
The absolute benefit appeared greatest in younger patients
in some studies (Evaluation of 7E3 for the Prevention of
Ischemic Complications [EPIC], Evaluation in PTCA to
Improve Long-term Outcome with abciximab GP IIb/IIIa
blockade [EPILOG], Evaluation of Platelet IIb/IIIa Re-
ceptor with Integrilin Therapy [EPISTENT]) (Fig. 2) but
was greatest in older patients in others (Enhanced Suppres-
sion of the Platelet IIb/IIIa Receptor with Integrilin Ther-
apy [ESPRIT], Integrilin to Minimize Platelet Aggregation
and Coronary Thrombosis II [IMPACT II]) (Fig. 1). No
efficacy data are available specifically for octogenarians, and
no safety data were presented in any of these analyses.
The absence of published data regarding the safety of GP
IIb/IIIa inhibitors in octogenarians leads to a clinical
dilemma for many cardiologists. Because of advanced age
and greater comorbidity, many clinicians are rightly con-
cerned that these drugs might have prohibitive risk in the
very elderly and might be associated with an increased risk
of intracranial bleeding, a problem not seen in the younger
patients enrolled in the randomized trials. The study by
Sadeghi et al. (15), published in this issue of the Journal,
helps alleviate these concerns and is thus an important
contribution. In addition to the large size of the octogenar-
ian cohort, one of the strengths of this study is that it
represents a “real world” experience of PCI in the very
elderly. These data are much more helpful to clinicians
trying to make difficult decisions than data from random-
Figure 1. Percentage of patients with the primary end point in the subgroup of patients 65 years of age (70 years old in the IMPACT II trial). Black
bars  placebo; white bars  drug.
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ized trials, because these data reflect common clinical
practice.
The main risk of parenteral platelet inhibitors is bleeding,
and this can be defined in many ways. Sadeghi et al. (15)
defined access site bleeding as any hematoma 3 cm. Using
this definition, Sadeghi et al. (15) found more access site
bleeding in patients treated with GP IIb/IIIa inhibitors
(26% vs. 20%). These numbers sound high and are greater
than bleeding rates reported in the randomized trials;
however, those trials had different definitions of bleeding. It
is unclear how many of these hematomas were “significant”
in terms of patient discomfort or led to a delayed discharge.
To gain a sense of perspective regarding these bleeds, the
investigators reported other indices of bleeding. Although
there were more bleeds defined as a hematocrit drop of more
than 10% (7.8% vs. 4.2%), there was no difference in
transfusion requirements between the groups, suggesting
that “serious” bleeding was not greatly increased in the
parenteral platelet inhibitor group. Non-access site bleeding
was also higher in the parenteral platelet inhibitor group,
but the absolute numbers did not appear alarming (5.2% vs.
2.6%) and consisted mostly of gastrointestinal and genito-
urinary bleeds. Importantly, there was no intracranial bleed-
ing, and there was no difference in the incidence of
retroperitoneal or pulmonary hemorrhage. Few patients
were treated with heparin post-intervention, which has been
recognized as an important strategy to prevent bleeding
with these drugs (14).
This study does not address the issue of efficacy. There
was a higher event rate in the GP IIb/IIIa inhibitor group,
but this is almost certainly due to the higher risk profile of
those selected for use of these drugs. The parenteral platelet
inhibitor group was more likely to have an acute coronary
syndrome or MI and more likely to undergo multi-vessel
PCI. No data on lesion type or complexity were reported,
and this may have been an important additional criterion
leading to the use of parenteral platelet inhibitors.
There are several important limitations of this study.
First, patients were selected for parenteral platelet IIb/IIIa
inhibitor use by unclear criteria (“at the operator’s discre-
tion”), and thus broad application of these data to all
octogenarians is not appropriate. It is certain that non-
quantifiable variables involving common sense and sound
clinical judgment were involved in selecting patients for this
treatment, and it is imperative that clinicians wishing to
apply these data to their own patients do the same. The
bleeding complications were not prospectively defined, and
no standardized system for data collection was performed.
Bleeding events were either reported by operators or ob-
tained by chart review, and this may have led to their
underestimation. Finally, this is a study primarily of eptifi-
batide; the results may have been different if a greater
proportion of patients were treated with abciximab or
tirofiban.
Although these data add substantially to our knowledge
regarding the use of this important class of drugs in an
ever-increasing and high-risk group of patients, there does
appear to be a need for a randomized trial to establish the
safety and efficacy of these drugs in this age group. This will
likely never be done. In the future, it is hopeful that
additional registry and outcome data will supplement the
study by Sadeghi et al. (15), providing information helpful
to clinicians caring for the very aged. For the time being, it
appears that the platelet GP IIb/IIIa inhibitors can be used
safely in selected octogenarians chosen to undergo PCI.
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